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After preliminary review of relevant research articles, the thesis was able to gain a 
deeper understanding of neurotechnological interventions (e.g. deep brain stimulation, and 
other neurostimulators), specifically in regards to their use in treatment of motor conditions 
(e.g. Parkinson’s, Epilepsy, etc.) and for some psychological disorders (e.g. depression, other 
mood disorders, etc.).  A scoping review was conducted on a specific class of treatments used 
for particular conditions: invasive neurotechnological treatments for mood disorders.  The 
reasoning behind this specified approach was due to the lack standardized policies and 
regulations in place for invasive neurotechnological interventions used for treatment of mood 
disorders – in contrast to more policies and regulations for non-invasive interventions.  
Therefore, the scoping review will attempt to cover research available based on other certain 
attributes, such as: current regulations (e.g. FDA guidelines and CMS rules), economic 
considerations, and any legal or ethical implications.  Last, from such review, the thesis will 
attempt to propose a recommended public health response to these treatments.  It is hoped 
that adoption of public health safeguards can ensure ethical and effective application of 
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There is a growing use of neurostimulators and other neurotechnological interventions 
as treatment for severe neurological ailments, typically as a last resort option for severe motor 
or mood disorders, such as Parkinson’s disease or treatment-resistant depressive 
disorder(Edwards C, 2017).   Neurostimulators can be defined as “active implantable devices 
that provide therapeutic intervention, sensory feedback or improved motor control via electric 
stimulation of neural or neuro-muscular tissue in response to trauma or disease.”(Shephard, 
R.L, 2018).  For the purposes of the thesis, neurostimulators will be used interchangeably with 
1) neurotechnological interventions, 2) neuromodulation techniques, and 3) neurostimulation 
treatments or devices.  Mood disorders will be used as a synonymous term for ‘psychiatric 
disorders.’  Mood disorders can encompass, but not be limited to 1) Treatment-Resistant 
Depression (TRD), 2) General Anxiety Disorder (GAD), and 3) Obsessive Compulsive Disorder 
(OCD).  Addiction disorders and others substance-related disorders may also be included when 
necessary.   
Common examples of invasive treatments used in treatment for mood disorders are 
Deep Brain Stimulation (DBS) and Vagal Nerve Stimulation (VNS). (Wong, 2018).  Other invasive 
neurostimulation techniques are “motor cortex stimulation (MCS), responsive neurostimulation 
(RNS), and spinal cord stimulation (SCS)” – but only have therapeutic use with movement 
disorders, not mood disorders(Edwards C, 2017).  Since most neurostimulators can be medical 
devices, they are also classified by federal regulatory bodies like the Food and Drug 
Administration (FDA)(Rome, 2014).  The FDA classifies medical devices based on their 
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respective risk level, with devices with lower risk levels belonging to Class I and II, and thus have 
“simple requirements for getting to the market” versus devices tiered into Class III  (Shepard R, 
2018).  Implantable devices are considered to be implantable neurostimulators and are an 
example of Class III devices.  Thus, they will typically have longer testing requirements due to a 
more stringent regulatory pathway which imposes additional testing (O’Neill T, 2019).   
In contrast, non-invasive neuromodulation devices are not surgically implanted into the 
patient (like they are in invasive treatments); thus, they are not ‘implantable’ medical devices 
(Wong, 2018).  Rather, non-invasive neurostimulation is the “process or technology that applies 
electrical currents, in varying parameters, by.... inhibition of specific neuronal groups, 
pathways, or networks.” (Edwards C, 2017).  Examples include repetitive transcranial magnetic 
stimulation (rTMS), which arguably is the most recommended neurostimulator for treatment-
resistant depression (McClintock S, 2018).  
Increased scientific research and innovation in the neurological fields have introduced 
more emerging, novel treatments.  As a result, there has been increased pressure on the FDA to 
modernize its rules for an expedited approval process (Berglund J, 2014).  Despite most 
treatments’ regulation under the FDA as Class III medical devices, there is still a public health 
risk due to the relatively lack of standardization among different treatment types (Krause J, 
2018).  For instance, some of the dangers posed from lack of standardized policies include 
potentially unenforced public safety safeguards which are intended to protect and promote 
public health(Krause J, 2014). 
A preliminary search of past literature reviews and relevant research has been 
conducted by the researcher.  Based on such review, findings show a lack of standardized 
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policies on the regulation of novel and emerging uses of invasive neurotechnological 
interventions for treatment of mood disorders.   
In contrast, there is a more regulatory guidance, as well as FDA approval, for use of 
noninvasive treatments for mood-related disorders (Shephard R, 2018)(Marjenin T, 2019).  
Therefore, it is hypothesized that there is arguably little research on utilization, evidence, and 
other applied areas with invasive neurotechnological treatments.  It is also predicted that there 
is lack of standardized policies and regulations in place, and by extension, no public health 
safeguards to ensure ethical and effective application of neurotechnological treatments for 
treating mood disorders. 
The abovementioned points to a notable gap in the body of research for 
neurostimulators, which this scoping review seeks to address.  Additional research on the 
treatment capabilities of invasive neurostimulators, as well as the risks posed by emerging 
implantable devices, is of value to the scientific community.  New research insights on emerging 
invasive neurostimulators can also help guide better-informed policies, which can benefit the 
public as well.  
Furthermore, the thesis serves to highlight potentially beneficial treatment options for 
serious psychological conditions.  Taking depression as one example, it is estimated to have a 
“lifetime prevalence of 15 to 20% in the United States [and be] the leading cause of years lost 
to disability worldwide, and is 1 of the top 3 contributors to global burden of disease.” 
(Filkowski M, 2017).  Given the magnitude of mental health conditions, it is imperative to 
consider the benefits and risks associated with invasive neurostimulators.  While noninvasive 
neurostimulators are approved for treatment in treatment-resistance depression, there is less 
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opportunities for invasive techniques to be available at treatment options (McGirr, 2018).  
Reasons for this delta may simply be due to lower amounts of FDA-approved options for 
invasive treatments and devices.  The following is supported by a recent report provided by the 
FDA’s Office of Neurological and Physical Medicine Devices (OHTS) as well as by the ‘larger 
literature’ that was reviewed during the scoping review process (Marjenin, T, 2019).   
Overall, a scoping review can be helpful to learn more about invasive neurostimulators’ 
capabilities with treating intractable mood disorders.  Although still limited in their medical 
application, further research and evaluation on such practices will be important to conduct.  It 
is the researcher’s objective that such scoping review can help evaluate and assess currently 
















A scoping  review will be conducted on select national databases, such as PubMed and 
Cochrane Database Syst Review.  There also may be additional inclusion of other research 
articles outside of the scoping review which are determined to be relevant enough for 
consideration.  The initial scoping review will be performed with reference to the PRISMA-ScR -
checklist (Tricco, 2018).  A scoping review was determined as best equipped to explore research 
on the potential treatment capabilities offered by invasive neurostimulators, specifically for 
mood disorders. Therefore, data on invasive neurotechnological interventions will be reviewed 
based on their categorical research area, including but not limited to: type of invasive 
treatment technique (e.g. DBS or VNS), specific mood disorders, study type, and applicable 
policies or regulations.   Based on the research findings, the thesis will suggest research 
implications for potential future studies seeking to understand any present research gaps with 
regards to invasive neurostimulators.   In sum, the research question driving the scoping 
strategy is: What are the regulations or policies for the different types of mood disorders which 
invasive neurostimulation techniques can treat? 
 
Search Strategy 
 A comprehensive search strategy is detailed in the Appendix, with a summarization 
detailed under Table !.  Searches were mostly conducted in Jan 24, 2020, and later to recheck in 
April 2020, in PubMed and Cochrane Database System Review.  Examples of search terms 
included were “Deep Brain Stimulation” or “DBS” or “Vagus Nerve Stimulation” or “VNS” or 
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“invasive neurostimulation” or “invasive brain stimulation” or “noninvasive brain stimulation” 
AND in combination of “mood disorders” or “major depressive disorder” or “MDD.”   
 The above query was also repeated for other purposes outside the scoping review, 
mainly to attain additional background information.  This will be done by adding other terms 
such as “recommendations” or “FDA” or “regulations” or “policies” or “economic evaluation” or 
“ethical.”  Synonymous terms and other associated terms were also employed in these 
searches.  Please reference the Appendix, Table I, and Figure ! for additional information on the 




Relevant studies which discussed invasive neurostimulation treatments for mood 
disorders, such as treatment-resistant depression (TRD) or obsessive-compulsion disorder 
(OCD), were included in the scoping review.  Some substance related disorders, such as 
anorexia nervosa (AN) or cocaine dependence were also included in the scoping review.  
However, studies which did not specify a particular type of substance abuse or drug addiction 
was not included.   Studies which discussed non-invasive treatments were not included. 
Inclusion criteria for studies was set by their research design, with most including studies being 
one of the following: randomized controlled trials (RCTs), evaluation studies, literature reviews, 
study protocols, and government guidelines.  Last, studies before the year 2017 were not 
included in the scoping review due to time and budget constraints.  More supplemental 
information can be referenced in the Appendix. 
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Table I: Summary of Data Extraction Process 




Additional Excluded (via Filtering): 99 
Studies Included: 6 
*added from individual hand search:  3 
Total Studies Included 9 





























No. (%) out of a 
total of 9 
Studies
DBS X X X X X X X X 8 (88.89%)
VNS X X X X X 5 (62.5%)
Treatment-
Resistant 
Depression X (with both) X (with VNS)
X (with 
VNS) X (with both)
X (with 
both) X (with both)
X (with 
both)
DBS: 5(62.5%);          
VNS: 7(77.78 )*





DBS: 3(33.33%)**          
VNS: 0(0% )




DBS: 1(62.5%)          
VNS: 0(0%)
Addictions 
X (DBS; for 
Cocaine 
Dependence)
DBS: 1(11.11%);          
VNS: 0(0% )

















Table III   - Important Information on Invasive Neurostimulators 
Type of Neuromodulation 
Technique 
Type of Mood Disorder Regulatory Status  
 
Deep Brain Stimulation  
Obsessive-compulsive disorder 
(OCD) 
Indication only; Class IIII (has HIE 
exemption since 2009) 
Anorexia Nervosa Limited off-label use; clinical 
evidence shows potential 
therapeutic use  
Drug Additions: Cocaine 
Dependence, Opioid Addiction 
Limited off-label use; clinical 




Mixed research findings; ongoing 
clinical trial  
  
Vagal Nerve Stimulation Treatment-Resistant 
Depression 
 
Indication only; Class III 

















Figure 1 – Charting Data Extraction Process: A Flow Chart  
   
 




















































Records identified through 
Cochrane database 
searching  
(n =3  ) 
Records identified through 
PubMed database searching  
(n = 389  ) 
Records after duplicates 
removed  (n =3  ) 
Total Records 
screened  
(n = 392) 
Records excluded (n = 287 ) 
(Unrelated topic, not  
English language, out of date range, 
country of study outside of North 
America) 
Records eligible 
for more screening 
(n = 105  ) 
Additional records excluded (n 
=100) 
(bioengineering focus, not 
related to subject, or out of 
new date range [before 2017]) 
Additional Records 
from Individual 
Hand Searches (n = 
3) 
Total # of Studies 
in scoping review 




The scoping review analyzed 9 studies, as detailed in Table 2.  Many dozens of other 
studies were excluded for variety of reasons, as described in Table I and Figure I.  Studies were 
excluded mostly for three main reasons: 1) published language was not English language or the 
journal was not in North America, 2) subject area of the research was unrelated to the thesis’s 
objective (e.g. being too focused on the biomedical engineering aspect of devices) and 3) 
focused on the wrong research areas of the scoping review (e.g. centered around “non-
invasive” treatments or movement disorders).  Supplemental exclusion criteria were set, which 
is listed in the Appendix. 
7 out of 9 studies in the scoping review (78% of total studies) were literature reviews 
(from PubMed) that looked at the therapeutic uses of invasive neurostimulators for mood 
disorders.  The remaining 2 studies (22% of total studies) were government issued guidelines 
concerning safety recommendations.  One study was a guideline issued from the federal level in 
Canada, while the other was at the U.S. state-level (McIntrye, 2018)(Milev, 2016).  Looking 
abroad to Canada, clinical guidelines issued for neurostimulation treatments used for the 
“management of adults with major depressive disorder”, encompassed 6 types of 
‘neurostimulation modalities’ – 4 of the 6 being noninvasive treatments (Milev, RV, 2016).  
Intriguingly this pattern is the same in the U.S., with the about 4 of 6 of FDA-approved 
neurostimulators being non-invasive treatments (Marjenin, T, 2019).  
Regarding the uses of invasive neurostimulation treatments, the scoping review found 
invasive neuromodulation treatments to be discussed in 9 of the 9 articles, as having 
therapeutic use for at least one mood disorder.  However,  the other 2 out of 9 focused on 
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addiction related disorders.  Overall, there was more emphasis on invasive treatments for 
certain mood disorders, a recurrent characteristic of those studies which will be discussed in 
greater detail in the Discussion and Conclusion section.   
On another note, FDA approval of an Early Feasibility Studies (EFF) investigational device 
exemption (IDE) was another indicator which was considered, but ultimately excluded.  Per one 
study, devices for neurological purposes composed of most EFF IDEs (Holmes, D.R; 2017) 
However, given the limited data from a small sample size of EFF IDEs – which were only 
available after 2016 (post-passage of the 21st Century Cures Act) – there is not much external 
validity and so was excluded from the scoping review.   
Thus, the majority of reviewed studies were 1) literature reviews on uses of invasive 
neurostimulators, and 2) specifically for the treatment of mood disorders. The scoping review 
also highlight noticeable patterns, as detailed in the Appendix and in Table 2.  Overall, most 
studies in the scoping review detailed invasive neurostimulators therapeutic uses in aiding 
patients with treatment-resistant depression.  Depression had the overall highest frequency in 
being mentioned as a potentially treatable condition by the two main invasive techniques we 
covered, VNS and DBS.  However, Deep Brain Stimulation was more commonly discussed as an 
intervention option, versus that of VNS.  DBS was most covered for its treatment capabilities 
with depression (5 out of 9 studies mentioning it), then next with ODC (per 3 out of 9 studies).   
Similarly, vagal nerve stimulation was also mostly commonly cited as an intervention for 
depression – and overall was the treatment type most mentioned for its therapeutic use with 





As discussed, it was noted that non-invasive treatments have historically (and 
consistently) been used more for treatment-resistant depression by physicians.  This is 
especially true for repetitive transcranial magnetic stimulation (rTMS) in its treatment for 
depressive disorders(McIntryre, 2018).  Meanwhile, invasive treatments have been cited less as 
treatments for major depression disorder, or in any other severe cases of mood disorders.  In 
fact, invasive neurostimulations are only approved for 2 indications, with DBS devices having a 
rare HDE exception pertaining OCD and VNS having an indicated use for treatment-resistant 
depression (Marjenin, T, 2019).  Thus, there is a gap between noninvasive and invasive 
neurostimulators, regarding its use in treating depression and other mood disorders.   
The scoping review explored invasive neurostimulation techniques in hopes of adding 
value to the abovementioned research area.  Overall, analysis of the conducted scoping review 
has thus far shown little information regarding invasive neurostimulation interventions as 
treatment option for mood disorders.   For instance, as detailed in Table II, the majority of both 
VNS and DBS studies mention their therapeutic use with treatment-resistant depression.  
However, this is not congruent with our findings for other severe psychological disorders, such 
as Bipolar Affective Disease, General Anxiety Disorder, and Schizophrenia – which were not 
substantially discussed in the articles included in the scoping review. Reasons for these findings 






Conclusion   
Summary of findings 
The scoping review did not find an abundance in information on invasive 
neurostimulators’ therapeutic use with treating most cited psychiatric disorders (e.g. Bipolar 
Disease, Attention Deficit-Hyperactive-Disorder, Bipolar, etc.) as we detailed in our results 
(Table 2 for results).  Treatment-resistant depression was the main exception to this rule, as 
well as OCD to a limited degree - with most of the included studies covering DBS’ promising on-
going research with potentially treating TRD and OCD.  It is also important to note that VNS is 
the only invasive neuromodulation technique which is currently FDA-approved for indicated use 
of TRD (Aaronson, 2018).  Hence, most of the reviewed studies on VNS were based off a larger 
amount of publicly available data, as VNS devices have been in the ‘marketplace’ longer than 
DBS for depression (Mertens, 2018).   
The current body of research points to the promising returns which VNS and DBS can 
bring as a last-resort treatment option for intractable mood disorders.  There is no doubt about 
the transformational health improvements which both invasive neurostimulator treatments can 
yield; however, there should be caution with attempts to prematurely challenge existing 
regulatory barriers which serve the public health (Loftus C, 2018).    
Furthermore, it is argued that the FDA’s authority to issue a Class III classification with 
invasive neuropsychiatric devices is not sufficient enough, given the lack of federal guidelines 
on invasive neurostimulators therapeutic use in psychiatric disorders (Krause,  ).  One proposed 
solution is to study the case of two noninvasive neurostimulators’ therapeutic use with mood 
disorders, which interestingly were able to change their regulatory pathway track from a PMA 
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pathway to a less stringent 501k pathway(Marjenin, 2019).  However, the contextual 
information is uncertain and remains speculative.  Even more, advocating for a less stringent 
approval process is not feasible for invasive neurostimulation devices, which are perceived to 
be riskier due to their ‘implantable’ nature (Filkowski, 2017).   
 
Limitations  
The scoping review presents limitations in the amount of research it was able to cover, 
given the relatively lack of FDA-approved invasive neuromodulation devices for mood and 
anxiety disorder.  The following limitation also guided our scoping review protocol with its 
search criteria for included studies – which had to be based off clinical trials or off-label use 
collected from 2017-2019.  There is also a lack of publicly available data on the utilization 
trends of invasive neurostimulators, as well as little research focused on either the economic or 
ethical considerations of their growing research and medical application.    While the scoping 
review identified these limitations, it can also be perceived as future opportunities to guide 
new and exciting research. 
 
Concluding Remarks and Final Recommendation 
The scoping review provides insights on potential roadblocks for further advancing the 
adoption of new neurostimulation treatments.  For instance, there is not much standardized 
guidelines from regulatory bodies on both approved indications and off-label uses of invasive 
neurostimulators for mood and anxiety disorders(Stahl, 2018 ).  In addition, not much economic 
evaluation or cost effect studies were able to be identified in the scoping review, and if they 
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were, they were exclusively for non-invasive neurostimulation treatments (Niyazoa, 
2018)(Voight, 201)(Mendlowitz, 2019).  
Hence, future studies can contribute by attempting to conduct an economic evaluation 
or a cost-effective analysis of treatment types for mood disorders.  Understanding the 
economic factors can be helpful not only to researchers, but also to all stakeholders: including 
physicians, patients (consumers), and device manufacturers (Rome, 2014).  Encouraging further 
adoption of standardized best practices from more established medical practices can be a 
valuable best practice to consider as well.  This is stressed since non-invasive treatments 
generally more clinical guidelines and safety recommendations for mood disorders than 
invasive treatments, which is also another research opportunity for future follow up studies 
(McClintock, 2018)(Perera, T, 2016).   
 Another case study worth considering for best practices is the relatively successful 
adoption of cardiac pacemakers in patient care; thus, improving patient’s health and also 
setting the framework for a new commercially successful market.  On a similar note, ensuring 
all stakeholders involvement in the regulatory approval process, including patients, is 
paramount to the adoption of novel new neurotechnological intervention(Bergland, 2014).   
In sum, the scoping review was able to identify the above areas where there is arguably 
a need for more research.  A final area also recommended for further research are other 
therapeutic applications of neurostimulators, such as in substance related disorders.  As 
evidenced in the scoping review, there is growing clinical evidence of potentially life-saving 
benefits which deep brain stimulation can have with treating patients afflicted with cocaine 
dependence and other drug addictions.  One therapeutic use for DBS can be with helping 
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individuals who are combating with Opioid Addiction. Further research and funds should invest 
in our efforts to combat this public health crisis – which can potentially be lifesaving for many 
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Appendix  A  - Supplemental Information for Scope Review  
 
PubMed Search – Search 1: 




("substance-related disorders"[MeSH Terms] OR "mood 
disorders"[MeSH Terms] AND "neurostimulation"[tw]) OR 









AND ( Review[ptyp] OR Meta-Analysis[ptyp] OR 
systematic[sb] OR Practice Guideline[ptyp] OR 
Guideline[ptyp] OR Evaluation Study[ptyp] OR Randomized 
Controlled Trial[ptyp] ) AND "last 5 years"[PDat] AND 
English[lang] AND ( systematic[sb] OR Review[ptyp] OR 
Guideline[ptyp] OR Meta-Analysis[ptyp] OR Practice 
Guideline[ptyp] OR Evaluation Study[ptyp] ) AND ( 










Change “AND last 5 years"[PDat  with “AND ( 
"2017/01/01"[PDat] : "2019/12/31"[PDat] )” 
 
10 entries 




PubMed Search – Search 2: 




(mood disorders[mh] OR substance-related disorders[mh]) 









AND ( Review[ptyp] OR Meta-Analysis[ptyp] OR 
systematic[sb] OR Practice Guideline[ptyp] OR 
Guideline[ptyp] OR Evaluation Study[ptyp] OR 
Randomized Controlled Trial[ptyp] ) AND "last 5 









Change “AND last 5 years"[PDat  with “AND ( 
"2017/01/01"[PDat] : "2019/12/31"[PDat] )” 
201 entries -> 39 -> 26 = 1  
26 entries 
removed 25 studies from failing to meet eligiblity 1 study (McGirr) 
26 
 
PubMed Search 3: 




substance-related disorders[mh] OR mood disorders[mh]) 










AND ( Review[ptyp] OR Meta-Analysis[ptyp] OR 
systematic[sb] OR Practice Guideline[ptyp] OR 
Guideline[ptyp] OR Evaluation Study[ptyp]) AND "last 5 








Change “AND last 5 years"[PDat  with “AND ( 
"2017/01/01"[PDat] : "2019/12/31"[PDat] )” 
 
33 entries 




Deviation from scoping protocol: 
 
*added from individual searches using disembogues terms and “similar articles” tabs on above 
searches: 3  (Milev, Park, Edwards) 
 
 
Cochrane System Review: 
 
MeSH Terms: Neuromodulation OR Invasive brain stimulation OR Deep brain stimulation OR 
DBS or Vagal nerve stimulation OR VNS 
 
3 systemic reviews were identified, but all 3 were excluded as they did not fit the 
inclusion strategy (were for movement conditions) 
 
 
 
